The Relationship of BMD Increases Between the First 12 Months and the Latter 12 Months by Daily Teriparatide Treatment

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Calcified Tissue International

• Publication date

  2016-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00223-016-0151-5PMID 27206528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Usefulness of daily teriparatide treatment in elderly patients over 80 years of age

  2016cited by this paper
• The Relationship of BMD Increases Between the First 12 Months and the Latter 12 Months by Daily Teriparatide Treatment

  2016cited by this paper
• Analysis of daily teriparatide treatment for osteoporosis in men

  2015cited by this paper
• Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients

  2014cited by this paper
• Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study.

  2014cited by this paper
• Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men

  2013cited by this paper
• An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide

  2013cited by this paper
• Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis

  2012cited by this paper
• PINP as an aid for monitoring patients treated with teriparatide.

  2011cited by this paper
• Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.

  2010cited by this paper
• Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment

  2008cited by this paper
• Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.

  2008cited by this paper
• The Effect of Prior Bisphosphonate Exposure on the Treatment Response to Teriparatide in Clinical Practice

  2007cited by this paper
• Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

  2007cited by this paper
• Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF‐II Immunoreactivity in Postmenopausal Women With Osteoporosis

  2006cited by this paper
• Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

  2005cited by this paper
• Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

  2005cited by this paper
• Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.

  2005cited by this paper
• Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

  2003cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001influential reference
• Diagnostic criteria for primary osteoporosis: year 2000 revision

  2001cited by this paper
• Clinical Interventions in Aging Dovepress

  year unknowncited by this paper

• Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study

  2022cites this paper
• Disruption of the aldehyde dehydrogenase 2 gene increases the bone anabolic response to intermittent PTH treatment in an ovariectomized mouse model.

  2020cites this paper
• Efficacy of Daily Teriparatide Treatment in Low Levels of Walking State Patients

  2017cites this paper